DeutschNewstral
Article
jdsupra.com on 2017-01-13 00:07
FDA Issues Newest Guidance Regarding Biosimilar Application Process
Related news
- FDA Issues Guidance Regarding Interchangeability of Biosimilar and Biologic Drugsjdsupra.com
- FDA Releases Biosimilar Naming Guidancejdsupra.com
- FDA Issues Draft Guidance on Biosimilar Interchangeabilityjdsupra.com
- FDA accepts Coherus’s resubmitted pegfilgrastim biosimilar applicationjdsupra.com
- BREAKING NEWS: FDA Denies Citizen Petitions Regarding Biosimilar Labelingjdsupra.com
- FDA Denies Amgen's Citizen Petition Regarding Biosimilar Applicant Requirementsjdsupra.com
- FDA Issues Guidance Regarding Biologic Drug Namingjdsupra.com
- FDA Issues Revised Guidance on Biosimilar Development and BPCIAjdsupra.com
- FDA Releases Draft Labeling Guidance for Biosimilar Productsjdsupra.com
- FDA Issues Final Guidance on “Labeling for Biosimilar Products”jdsupra.com
- FDA Issues Biosimilar Guidance for Label Carve-Outs and Supplementsjdsupra.com
- FDA Issues Guidance for Applicants Seeking Biosimilar/Interchangeable Approvaljdsupra.com
- FDA Guidance for Biosimilar Labeling Largely Stays with Generic Modeljdsupra.com
- FDA Issues Draft Guidance on Labeling For Biosimilar Productsjdsupra.com
- FDA Issues Final Guidance Requiring Meaningless Suffixes for Biosimilar Namesjdsupra.com
- FDA guidance may ease path to biosimilar interchangeabilityjdsupra.com
- FDA and FTC Announce Collaboration to Promote Biosimilar Competition; FDA Issues Draft Promotional Guidancejdsupra.com
- FDA Issues Another Draft Guidance Regarding Biosimilar Interchangeabilityjdsupra.com
- Lannett to Meet with FDA on June 9 Regarding Insulin Glargine Biosimilarjdsupra.com